


What is claimed is:

1. A compound according to Formula (I) hereinbelow:



(I)

- 5 wherein R1 is selected from the group consisting of straight or branched chain lower alkyl group having from 1 to 6 carbon atoms;  
 R2 and R3 are, independently, selected from the group consisting of straight or branched chain lower alkyl groups(having from 1 to 6 carbon atoms, cycloalkyl groups (having from 5 to 6 carbon atoms), cycloalkyl-alkyl (having 6 to 10 carbon  
 10 atoms), 2-thienyl, 2-pyridyl, phenyl, phenyl substituted with an alkyl group having not in excess of 4 carbon atoms, and phenyl substituted with an alkoxy group having not in excess of 4 carbon atoms; and  
 X<sup>-</sup> represents an anion associated with the positive charge of the N atom.
- 15 2. A compound according to claim 1 wherein the orientation of the alkyl chain attached to the tropane ring is endo.
3. A compound according to claim 2 selected from the group consisting of:  
 (3-*endo*)-3-(2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide;  
 20 and  
 (3-*endo*)-3-(2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane 4-methylbenzenesulfonate;
4. A compound according to claim 1 wherein X<sup>-</sup> is selected from the group  
 25 consisting of chloride, bromide, iodide, sulfate, benzene sulfonate and toluene sulfonate.

5. A pharmaceutical composition for the treatment of muscarinic acetylcholine receptor mediated diseases comprising a compound according to claim 1 and a pharmaceutically acceptable carrier thereof.
- 5 6. A method of inhibiting the binding of acetylcholine to its receptors in a mammal in need thereof comprising administering a safe and effective amount of a compound according to claim 1.
7. A method of treating a muscarinic acetylcholine receptor mediated disease,  
10 wherein acetylcholine binds to said receptor, comprising administering a safe and effective amount of a compound according to claim 1.
8. A method according to claim 7 wherein the disease is selected from the group consisting of chronic obstructive lung disease, chronic bronchitis, asthma,  
15 chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis.
9. A method according to claim 7 wherein administration is via inhalation via the mouth or nose.
- 20 10. A method according to claim 7 wherein administration is via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler.
- 25 11. A method according to claim 7 wherein the compound is administered to a human and has a duration of action of 12 hours or more for a dose of up to 1 mg.
12. A method according to claim 11 wherein the compound has a duration of action of 24 hours or more.
- 30 13. A method according to claim 12 wherein the compound has a duration of action of 36 hours or more.